Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1929)	10/3/2007 3:26:53 PM
From: Jibacoa	Read Replies (1) of 3722

After doubling in price from its Aug 27 L of $4.98 to its intraday H of $9.86 on Sep 26 SNTA met with some resistance & "profit taking".<g> But it is now up for 3rd day on a roll after some positive comments from Rodman & Renshaw, which initiated coverage with a "Market Outperform" rating and a $16 price target.<g> bigcharts.marketwatch.com In Sep 2006, SNTA reported positive results from a PIIb of its STA-4783 in 81 patients with malignant melanoma, which reportedly reached its primary endpoit. A PIII is expected to start on the 4thQ with more than 600 patients at 150 cancer centers worldwide. SNTA has stated it expects to sign a partnership for STA-4783 by the end of 2007. SNTA is also developing STA-9090 and STA-9584, which are in preclinical development; and Oral CRAC ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. Will see how SNTA handles its resistance at the $10 level. bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next